STAT+: Once again, the viability of the U.S. biosimilar market is thrown into question
Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system billions of dollars, Peter Bach and Mark Trusheim remain unconvinced.
So the high-profile skeptics have refreshed their controversial, two-year-old argument for overhauling the approach for making alternative versions of pricey biologic medicines available to the American public.
Continue to STAT+ to read the full story…
